Brokers Offer Predictions for Atossa Genetics Q1 Earnings

Atossa Genetics Inc. (NASDAQ:ATOS) – Research analysts at Ascendiant Capital Markets lowered their Q1 2026 earnings estimates for shares of Atossa Genetics in a report released on Thursday, April 9th. Ascendiant Capital Markets analyst E. Woo now anticipates that the company will post earnings per share of ($1.10) for the quarter, down from their previous forecast of ($1.05). Ascendiant Capital Markets has a “Buy” rating and a $24.00 price objective on the stock. The consensus estimate for Atossa Genetics’ current full-year earnings is ($0.22) per share. Ascendiant Capital Markets also issued estimates for Atossa Genetics’ Q2 2026 earnings at ($1.10) EPS, Q3 2026 earnings at ($1.10) EPS, Q4 2026 earnings at ($1.10) EPS, FY2026 earnings at ($4.40) EPS and FY2027 earnings at ($4.38) EPS.

A number of other brokerages also recently weighed in on ATOS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Atossa Genetics in a report on Wednesday, January 21st. HC Wainwright boosted their price target on Atossa Genetics to $25.00 and gave the stock a “buy” rating in a report on Thursday, March 26th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $36.33.

Atossa Genetics Price Performance

Shares of NASDAQ:ATOS opened at $5.74 on Wednesday. Atossa Genetics has a 1 year low of $3.76 and a 1 year high of $19.35. The stock has a market capitalization of $49.42 million, a price-to-earnings ratio of -1.60 and a beta of 1.34. The company’s 50 day simple moving average is $4.84 and its 200 day simple moving average is $9.25.

Hedge Funds Weigh In On Atossa Genetics

Institutional investors have recently made changes to their positions in the stock. Hudson Bay Capital Management LP acquired a new stake in shares of Atossa Genetics in the 2nd quarter valued at about $26,000. Gallagher Capital Advisors LLC acquired a new position in Atossa Genetics during the 3rd quarter worth approximately $27,000. JPMorgan Chase & Co. boosted its holdings in Atossa Genetics by 1,294.2% in the third quarter. JPMorgan Chase & Co. now owns 38,215 shares of the company’s stock worth $33,000 after acquiring an additional 35,474 shares in the last quarter. &PARTNERS bought a new position in Atossa Genetics in the fourth quarter worth approximately $25,000. Finally, Bank of America Corp DE grew its stake in Atossa Genetics by 55.7% in the second quarter. Bank of America Corp DE now owns 99,601 shares of the company’s stock valued at $83,000 after acquiring an additional 35,629 shares during the period. Institutional investors and hedge funds own 12.74% of the company’s stock.

Key Stories Impacting Atossa Genetics

Here are the key news stories impacting Atossa Genetics this week:

• Positive Sentiment: Ascendiant retained a “Buy” rating and a $24 price target, which supports bullish investor sentiment despite the model cuts. MarketBeat report
• Positive Sentiment: Technical/volume backdrop is constructive — volume is running above average and the stock sits above its 50‑day moving average, which can attract momentum buyers. MarketBeat trading data
• Neutral Sentiment: Ascendiant published multi‑year model assumptions for 2026–2027 (quarterly losses ~($1.09)–($1.10); FY2026 and FY2027 aggregate loss forecasts shown), which give investors updated guidance assumptions but do not change the firm’s target. MarketBeat report
• Negative Sentiment: Ascendiant lowered its EPS estimates for Q1–Q4 2026 (each trimmed to ($1.10) from ($1.05) previously) and cut FY2026 loss to ($4.40) from ($4.20), signaling larger near‑term cash burn or slower progress vs. prior expectations. That deterioration in near‑term profitability is a clear negative catalyst. MarketBeat report

Atossa Genetics Company Profile

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.